Neurology

Avalyn Pharma Appoints Business Operations Leader, Melissa Rhodes, to the Role of Chief Operating Officer

Seattle, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies…

10 months ago

TeraRecon Applauded by Frost & Sullivan for Solving Time-related Challenges in Neurological Care and Its Market-leading Position

TeraRecon partners with different vendors to provide precise, AI-supported patient care and expand in the neurological solutions market and other…

10 months ago

BioVie Hosting Virtual KOL Event on NE3107 in Alzheimer’s Disease Today, September 7, 2023

CARSON CITY, Nev., Sept. 07, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company…

10 months ago

Bausch Health’s Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA(R)

LAVAL, QC / ACCESSWIRE / September 6, 2023 / Bausch + Lomb Corporation (NYSE/TSX:BLCO), a subsidiary of Bausch Health Companies…

11 months ago

Milestone Achievement: Waypoint GPS Assists Dr. Stephen Banco in Groundbreaking First-in-Man Spine Surgery

READING, PA / ACCESSWIRE / September 5, 2023 / Dr. Stephen Banco, a nationally recognized orthopedic spine surgeon, has achieved…

11 months ago

Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress

New interim data from ongoing Phase 2b X-TOLE open-label extension demonstrates improvement in overall quality-of-life (QoL) when compared to baseline…

11 months ago

BioVie to Host Virtual KOL Event on NE3107 in Alzheimer’s Disease on September 7, 2023

CARSON CITY, Nev., Aug. 31, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company…

11 months ago

Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023

PHILADELPHIA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and five posters…

11 months ago

Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up

19.3 month significant survival difference for CNM-Au8® treated participants versus placebo52% significant decreased risk of ALS clinical worsening events Over…

11 months ago

Satellos Bioscience Announces Q2 2023 Financial Results and Operational Highlights

$48.7 million in cash and cash equivalents at June 30, 2023, providing expected runway to advance Company's development candidate ("DC")…

11 months ago